<DOC>
	<DOCNO>NCT00457691</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy FOLFIRI ( Irinotecan , Leucovorin 5 Fluorouracil ) chemotherapy combine sunitinib FOLFIRI chemotherapy without add sunitinib first line treatment patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>On June 25 , 2009 , independent Data Monitoring Committee ( DMC ) review progress Study A6181122 . The DMC determine Study A6181122 meet pre-specified futility criterion unlikely meet primary endpoint demonstrate statistically significant improvement progression-free survival ( PFS ) patient treat sunitinib plus FOLFIRI versus placebo plus FOLFIRI . No new safety finding note . Pfizer notify clinical trial investigator involve study regulatory agency finding . Patients receive benefit treatment determine investigator may remain study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Confirmed ( histologically cytologically ) colorectal adenocarcinoma metastatic disease . Not receive previous therapy metastatic colorectal disease FOLFIRI treatment clinically indicate . Adequate organ function define blood test . History another primary cancer last 3 year . Previous full field radiotherapy within last 4 week limited field radiotherapy within 2 week enrol study . Or previous radiation treatment 30 % bone marrow . History presence brain metastasis , spinal cord compression carcinomatous meningitis leptomeningeal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>colorectal neoplasm</keyword>
</DOC>